Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer
- PMID: 17070244
- DOI: 10.1016/j.juro.2006.07.075
Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer
Abstract
Purpose: We review our 20-year experience with salvage radical prostatectomy to determine prognostic variables predictive of oncological control of radiorecurrent prostate cancer. Using a standardized questionnaire we also evaluate outcome data regarding the long-term sexual and urinary effects of salvage radical prostatectomy.
Materials and methods: Between 1983 and 2002 salvage radical prostatectomy was performed in 51 patients with locally recurrent prostate cancer following definitive radiotherapy. Clinical information was obtained from a prospective database. Quality of life data were collected using the UCLA Prostate Cancer Index, a validated, patient administered instrument.
Results: At 5 years 47% of patients were progression-free without androgen deprivation therapy. Among patients with pT2 disease 100% were progression-free at 5 years, compared with 35% of patients with pT3N0 disease or higher and 0% of patients with node positive (pTxN+) disease (p < 0.001). Preoperative PSA 5.0 ng/ml or less was predictive of organ confined disease, and strongly associated with prolonged progression-free and overall survival (p < 0.001 and 0.01, respectively). Mean urinary function scores for patients with or without an artificial urinary sphincter compared favorably with scores reported after standard, nonsalvage prostatectomy. Sexual dysfunction was nearly uniform in patients undergoing standard salvage radical prostatectomy but implantation of a penile prosthesis was associated with a clinically significant improvement in sexual function.
Conclusions: When initiated early in the course of recurrent disease, salvage radical prostatectomy provides excellent oncological control of radiorecurrent prostate cancer without the need for androgen ablation. Implantation of an artificial urinary sphincter and inflatable penile prosthesis devices in patients with postoperative urinary incontinence or erectile dysfunction results in significantly improved quality of life parameters.
Similar articles
-
Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):448-53. doi: 10.1016/j.ijrobp.2004.09.049. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890586
-
Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited.J Urol. 2000 Dec;164(6):1998-2001. J Urol. 2000. PMID: 11061900
-
Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.J Urol. 1999 Mar;161(3):857-62; discussion 862-3. J Urol. 1999. PMID: 10022701
-
Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy.Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1530-5. doi: 10.1016/j.ijrobp.2003.09.082. Int J Radiat Oncol Biol Phys. 2004. PMID: 15050333 Review.
-
Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.J Clin Oncol. 2005 Nov 10;23(32):8198-203. doi: 10.1200/JCO.2005.03.1468. J Clin Oncol. 2005. PMID: 16278473 Review.
Cited by
-
Multi-Parametric MRI-Directed Focal Salvage Permanent Interstitial Brachytherapy for Locally Recurrent Adenocarcinoma of the Prostate: A Novel Approach.J Cancer. 2013;4(2):146-51. doi: 10.7150/jca.5419. Epub 2013 Feb 1. J Cancer. 2013. PMID: 23412660 Free PMC article.
-
Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.Cancer Med. 2018 May;7(5):1794-1801. doi: 10.1002/cam4.1443. Epub 2018 Mar 25. Cancer Med. 2018. PMID: 29577651 Free PMC article.
-
A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.Cancer. 2015 Sep 1;121(17):2942-50. doi: 10.1002/cncr.29421. Epub 2015 May 18. Cancer. 2015. PMID: 25989179 Free PMC article. Clinical Trial.
-
Role of surgery in high-risk localized prostate cancer.Curr Oncol. 2010 Sep;17 Suppl 2(Suppl 2):S25-32. doi: 10.3747/co.v17i0.705. Curr Oncol. 2010. PMID: 20882128 Free PMC article.
-
The spectrum of prostate cancer care: from curative intent to palliation.Curr Urol Rep. 2007 May;8(3):245-52. doi: 10.1007/s11934-007-0013-9. Curr Urol Rep. 2007. PMID: 17459275 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous